Clinical Trials Browser

Observational × lorlatinib × Clear all

NCT07556549 2026-05-22

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Active not recruiting

Non-Small Cell Lung Cancer ALK-positive

NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

73 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Enrolling by invitation

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

NCT06690541 2024-11-15

COMLORLA

Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04753658 2024-09-23

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

15 enrolled 22 charts

Neuroblastoma

NCT06532149 2024-08-09

EROS

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Carcinoma, Non-Small-Cell Lung

NCT06410040 2024-05-10

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Active not recruiting

Brain Neoplasms, Meningeal Carcinomatosis

NCT06361589 2024-04-12

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

ALK-positive Non-small Cell Lung Cancer

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC

NCT05167500 2023-03-30

LORLAPULM

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasm Metastasis